378 related articles for article (PubMed ID: 34146382)
1. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract][Full Text] [Related]
2. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
3. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
8. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
10. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
11. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
14. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
Senel F
Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
[TBL] [Abstract][Full Text] [Related]
17. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Receptor-Defined Breast Cancer Subtypes Between German and Sudanese Women: A Facility-Based Cohort Study.
Sengal AT; Haj Mukhtar NS; Vetter M; Elhaj AM; Bedri S; Hauptmann S; Thomssen C; Mohamedani AA; Wickenhauser C; Kantelhardt EJ
J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30241184
[TBL] [Abstract][Full Text] [Related]
19. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
20. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]